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ABSTRACT 
In the present study, the ethanolic extracts of fourteen wild edible mushrooms were 
investigated for their anti-inflammatory potential in LPS (Lipopolysaccharide) activated 
RAW 264.7 macrophages. Furthermore the extracts were chemically characterized in terms 
of phenolic acids and related compounds. The identified parent molecules (p-
hydroxybenzoic, p-coumaric and cinnamic acids) and their synthesised glucuronated and 
methylated derivatives obtained by chemical synthesis were evaluated for the same 
bioactivity, in order to establish a structure-activity relationship, and to understand the 
contribution of the compounds to the activity of the extracts. The extract Pleurotus ostreatus, 
Macrolepiota procera, Boletus impolitus and Agaricus bisporus revealed the strongest anti-
inflammatory potential, presenting also the highest concentration in cinnamic acid, which 
was also the individual compound with the highest anti-inflammatory activity. The 
derivatives of p-coumaric acid revealed the strongest properties, especially the compound 
CoA-M1, that exhibited a very similar activity to the one showed by dexamethasone used as 
anti-inflammatory standard; by contrast, the p-hydroxybenzoic derivatives revealed the 
lowest inhibition of NO production. All in all, whereas the conjugation reactions change the 
chemical structure of phenolic acids and may increase or decrease their activity, the 
glucuronated and methylated derivatives of the studied compounds are still displaying anti-
inflammatory activity. 
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CHAPTER 1. INTRODUCTION 
  
1.1. Inflammation and conventional anti- inflammatory drugs 
 
Inflammation is considered to be part of the complex biological response to remove injury or 
harmful stimuli such as pathogens, damaged cells, or irritation and this is a central feature of 
many pathophysiological conditions such as atherosclerosis, obesity, metabolic syndrome, 
diabetes (Pradhan, 2007) and even several types of cancers (Moro et al., 2012). 
 
When cells are exposed to immune stimulants, the pro-inflammatory cells, such as 
macrophages, monocytes, or other host cells, start to produce cytokines and other mediators, 
which initiate the inflammation process. Among the various inflammatory mediators, the 
most common are interleukins (IL-1β, IL-6, IL-8), tumour necrosis factor (TNF-α), nuclear 
factor-κB (NF-κB), intercellular adhesion molecule-1 (ICAM-1), inducible type 
cyclooxygenase- (COX-2), prostaglandin E2 (PGE2), 5-lipooxygenase (5-LOX), and 
inducible nitric oxide synthase (iNOS), which leads to the production of reactive nitrogen 
species such as nitric oxide (NO). Overproduction of these inflammatory mediators lead to 
different kinds of cell damage (Kanwar et al., 2009).  
 
Macrophages are large specialized cells that engulf and digest cellular debris, microbes, and 
cancer cells in a process called phagocytosis. More than a century has passed since 
Metchnikoff in 1892 first termed large phagocytotic cells ``macrophages`` and described 
their presence in the spleen, liver and connective tissues of vertebrates where they display 
anatomical and functional diversity (Takahashi, 2000). They play important role in non-
specific host defence mechanism and help to initiate other defence mechanisms. Beyond 
stimulating the immune system, macrophages play a crucial role in the inflammatory 
response through the release of a variety of factors, such as NO, prostaglandin mediators and 
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), in response to an activating stimulus, e.g. 
lipopolysaccharide (Moro et al., 2012). 
 
The class of anti-inflammatory drugs (steroidal and non-steroidal) are among the most widely 
prescribed groups of medicines in clinical practice worldwide. Recently, the nonsteroidal 
anti-inflammatory drugs (NSAIDs) are usually the most commonly administrated drugs to 
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reduce inflammation in the body. Many studies, however, have shown that the long-term 
administration of NSAIDs has the potential for significant side effects on the gastrointestinal 
tract with numerous harmful effects such as mucosal lesions, bleeding, peptic ulcers, and 
intestinal perforation (Dugowson et al., 2006). Recent studies show that NSAIDs are also 
associated with a relatively high incidence of renal adverse drug reactions, nephrotic 
syndrome, high blood pressure, acute tubular necrosis and cardiovascular toxicity (Elsayed et 
al., 2014). In this context, the discovery of new prototypes with improved anti-inflammatory 
activity and therapeutic safety is one of the targets in the area of research, development and 
innovation of the pharmaceutical industry. 
 
The anti-inflammatory action of NSAIDs can be explained by the effect of inhibiting the 
enzyme COX, which is responsible for the synthesis of prostaglandins, mediators with a great 
ability to induce inflammation (Tanaka et al., 2009). COX has two isoforms: COX-1 and 
COX-2. The first is constitutively expressed in a wide variety of cells, promoting 
physiological functions, such as gastric mucosal protection, control of renal blood flow, 
hemostasis, autoimmune responses, lungs, central nervous system, cardiovascular system and 
reproductive functions (Grosser et al., 2006). On the other hand, COX-2 is an inductive 
enzyme, which is expressed significantly due to various stimuli such as cytokines, endotoxins 
and growth factors. COX-2 originates inducing prostaglandins, which contribute to the 
development of the four cardinal signs of inflammation: pain, heat, redness and swelling 
(Fitzgerald, 2004), thus being considered as the main target for the anti-inflammatory action. 
In this context, the recently developed coxibs act through selective inhibition of COX-2. 
However, although inductive, this COX isoform is also expressed in normal vascular 
endothelial cells, synthesizing prostacyclin, an important substance in maintaining the 
prothrombotic/antithrombotic blood balance (Antman et al., 2007), which can trigger severe 
cardio-vascular problems. 
 
 
 
 
 
 
 
Screening in phenolic extracts, individual parent molecules and synthesized glucuronated and methylated derivatives 
3 
Oludemi Taofiq Ayodele 
 
1.2. Mushrooms as a source of alternative anti-inflammatory compounds 
 
Mushrooms are macrofungi with distinctive and visible fruiting bodies (Figure 1) that are 
either epigeous with fruiting bodies above the ground or hypogeous with underground 
fruiting bodies (Hesham et al., 2013). 
 
Mushrooms have been widely appreciated all over the world not only for their nutritional 
properties (Kalac, 2009), but also for their pharmacological value related with their richness 
in many bioactive metabolites of high medicinal value such as lectins, polysaccharides, 
phenolic compounds, terpenoids, ergosterol and derivatives, and volatile organic compounds 
(Hesham et al., 2013). They have been described as sources of important bioactive 
compounds such as antioxidants (Puttaraju et al., 2006; Ferreira et al., 2009, Heleno et al., 
2015), antitumors (Moradali et al., 2007; Ferreira et al., 2010, Carocho et al 2013), 
antimicrobials (Alves et al., 2012; Alves et al., 2013), immunomodulators (Borchers et al., 
2008), antiatherogenics (Mori et al., 2008) and hypoglycemic (Hu et al., 2006) compounds. 
Due to these properties, they have been recognized as functional foods, and as a valuable 
source of natural medicines and nutraceuticals (Lindequist et al., 2005; Guillamón et al., 
2010; Heleno et al., 2013).  
 
 
Figure 1. Structure of a mushroom with mycological terms used (Kalac, 2009). 
 
Moreover, mushrooms have also demonstrated some anti-inflammatory potential based on 
their ability to reduce the production of inflammatory mediators (Padilha et al., 2009; Elsayed 
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et al., 2014). Previous research studies have been carried out on this regarding with several 
mushroom species. For example, water, methanolic, ethanolic, and ethyl acetate extracts of 
different mushrooms showed significant decreases in the activities of inflammatory mediators 
such as NO, cytokines, and prostaglandins, thus inhibiting some macrophage functions and 
reducing cell inflammations (Table 1). Different compounds have been pointed out as the 
responsible for the anti-inflammatory activity such as β-glucans (Nosálóva et al., 2001), 
triterpenes (Ma et al., 2013, Choi et al., 2014), glycoproteins (Gunawardena et al., 2014) and 
even phenolic compounds (Moro et al., 2012). However, not too much is known about the 
phenolic bioactive forms in vivo; these compounds are metabolized and circulate in the 
organism as glucuronated, sulfated and methylated metabolites, displaying higher or lower 
bioactivity (Heleno et al., 2015). 
 
Table 1. Some previous studies on anti-inflammatory activity of different mushroom species evaluated through 
NO assay. 
Species Country Extract 
Inhibition of NO 
production 
References 
Agaricus bisporus 
Spain Methanol 30% at 0.5 mg/mL Moro et al., 2012 
Australia Ethanol 50% at 0.032 mg/mL Gunawardena et al., 2014 
Boletus edulis Spain Methanol 10% at 0.5 mg/mL Moro et al., 2012 
Cantharellus cibarius Spain Methanol 70% at 0.5 mg/mL Moro et al., 2012 
Caripia montagnei Brazil 
Acetone 80%, 
methanol 
43% at 10 mg/kg 
54% at 30 mg/kg 
49% at 50 mg/kg 
Queiroz et al., 2010 
Craterellus 
cornucopoides 
Spain Methanol 55% at 0.5 mg/mL Moro et al., 2012 
Flammulina velutipes Australia Ethanol 50% at 0.024 mg/mL Gunawardena et al., 2014 
Inonotus obliquus 
China Ethanol 65% at 40 µg/mL Ma et al., 2013 
South 
Korea 
Ethanol 50% at 89 µg/mL Park et al., 2005 
Lactarius deliciosus Spain Methanol 40% at 0.5 mg/mL Moro et al., 2012 
Lentinus edodes Australia Ethanol 50% at 0.027 mg/mL Gunawardena et al., 2014 
Pleurotus ostreatus 
Australia Ethanol 50% at 0.077 mg/mL Gunawardena et al., 2014 
Spain Methanol 15% at 0.5 mg/mL Moro et al., 2012 
Pleurotus tuber-regium Belgium Ethanol 70% at 0.5 mg/mL Liu et al., 2014 
Tricholoma matsutake 
South 
Korea 
Dichloromethane 47% at 2 mg/mL Lim et al., 2007 
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1.2.1. Carbohydrates 
Carbohydrates have been known to possess some interesting biological activity in terms of 
prevention and treatment of common diseases (Villares, 2013). Mushrooms have been known 
as a valuable source of bioactive carbohydrates hence, several polysaccharides and bioactive 
carbohydrates have been extracted from these species (Villares, 2013).  
 
Polysaccharides can be considered as one of the main group of carbohydrate compounds 
occurring in mushrooms that are responsible for a great range of healthy properties. They are 
the major components in mushrooms and the total content ranges from 35% to 70% in dry 
weight. Most of the carbohydrates in mushrooms are non-digestible carbohydrates (dietary 
fiber) including oligosaccharides (e.g., trehalose) and cell wall polysaccharides (e.g. chitin, β-
glucans (Figure 2) and mannans) (Cheung, 2010; 2013).  
 
 
 
Figure 2. Basic chemical structure of β-glucans. 
 
Several studies have shown the potential of polysaccharides as anti-inflammatory agents; the 
methanolic extract of Caripia montagnei (Berk.) Kuntze, was studied and the results suggest 
that its glucans are effective immunomodulators with anti-inflammatory potential (Queiroz et 
al., 2010).  
 
Furthermore, the aqueous extract of fuco-galactan from Agaricus bisporus (J.E. Lange) Emil J. 
Imbach, exhibited anti-inflammatory response in male Swiss mice (Elsayed et al., 2014). 
Different structural patterns have been found within the polysaccharides extracted from 
mushrooms. In this field, it is generally accepted that the β(1→3),(1→6)-linked 
carbohydrates play an important role in enhancing the antitumor and the immunomodulatory 
effects. 
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1.2.2. Terpenes 
 
Terpenes are a large and diversified group of organic compounds occurring widely in plants, 
macrofungi and animals, and empirically regarded as built up from isoprene, a hydrocarbon 
consisting of five carbon atoms with molecular formula (C5H6)n as building blocks (Hesham 
et al., 2013). The terpene compounds are named based on the number of repeated units of 
terpene building blocks, for example, monoterpenes (10 carbons), sesquiterpenes (15 
carbons), diterpenes (20 carbons), sesterterpenes (25 carbons), triterpenes (30 carbons), and 
tetraterpenes (40 carbons). These compounds exist widely in plants as the main components 
of resin and essential oil. In macrofungi, terpenes are present in modified forms (terpenoids 
or isoprenoids) and show biological activities with potential medical applications (Hesham et 
al., 2013). 
 
 
Figure 3. Chemical structure of lanostane. 
 
Mushrooms belonging to Ganoderma sp., such as Ganoderma lucidum (Curtis) P. Karst., and 
Ganoderma applanatum (Pers.) Pat., are known for their high content of triterpenoids, for 
example, lanostane (Figure 3), which shows immumomodulating and anti-infective activities 
(Jeong et al., 2008). Choi et al. (2014) investigated the anti-inflammatory effects of 12 
triterpenes from G. lucidum, determining whether these triterpenes inhibit LPS induced NO 
production as a marker for inflammatory responses in RAW264.7 cells. (Dudhgaonkar et al., 
2009). The authors evaluated the anti-inflammatory effects of the triterpene extract from G. 
lucidum in LPS-stimulated macrophages and the results were found to be interesting.  
Recent research has shown that some G. lucidum terpenes can prevent drug nephrotoxicity 
and inflammation, suggesting that they may have pharmacological applications (Elsayed et 
al., 2014). 
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1.2.3. Peptides 
 
Peptides have been the target of intense research and development in recent years by the 
pharmaceutical and biotechnology industry. Bioactive proteins and peptides were reported 
from many sources ranging from bacteria, plants, macrofungi to humans. Many of them show 
bioactive characteristics like antibacterial, antifungal, antiparasitic, antihypertensive, 
antisporadical, and anticancer activities, among many others. 
 
In addition to the previous bioactive compounds, anti-inflammatory peptides of different 
molecular weights have been isolated from mushrooms. A low molecular weight peptide 
known as Cordymin with molecular weight of 10,906 Da, has been identified and purified 
from the medicinal mushrooms Cordyceps sinensis (Berk.) G. H. Sung, J. M. Sung, Hywel-
Jones and Spatafora, and Cordyceps militaris (L.) Fr. (Wang et al., 2012). This peptide 
significantly inhibited the infiltration of polymorphonuclear cells and IR-induced up-
regulation of C3 protein produced in the brain, interleukin-1β, and TNF-α, which had a 
neuroprotective effect on the ischemic brain, due to the inhibition of inflammation. Also, 
another important anti-inflammatory peptide is Agrocybin that has been isolated from the 
edible mushroom Agrocybe cylindracea (V. Brig.) Singer (Elsayed et al., 2014). 
 
1.2.4. Phenolic Compounds  
 
Mushrooms have been known to produce an amazing diversity of secondary metabolites. One 
of the most important groups of these metabolites are phenolic compounds. Phenolics are 
characterized by at least one aromatic ring (C6) bearing one or more hydroxyl groups (Rice-
Evans et al., 1997). Phenolic compounds, including phenolic acids, are a group of 
secondary metabolites from fungi and plants secreted for protection against UV light, insects, 
viruses and bacteria (Heleno et al., 2015). 
The term phenolics encompasses approximately 8000 naturally occurring compounds and 
current classification divides the broad category of phenols into several different groups, 
distinguished by the number of constitutive carbon atoms in conjunction with the structure of 
the basic phenolic skeleton (simple phenols, benzoic acids, phenylopropanoids and 
flavonoids; Michalak, 2006). Phenolic compounds have received considerable attention for 
being potentially protective factors against cancer and heart diseases, in part because of their 
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potent antioxidative properties and their ubiquity in a wide range of commonly consumed 
foods (Jahangir et al., 2009). Furthermore, Kim et al. (2012) described corn bran (80% 
ethanolic extract) as a source of anti-inflammatory agents such as four hydroxycinnamic acid 
derivatives, including two free cinnamic acids, p-coumaric acid and ferulic acid, and their 
conjugate phenolic amides, p-dicoumaroylputrescine and diferuloylputrescine.  
 
1.3. The particular case of phenolic acids 
 
Phenolic acids are synthesized from the shikimate pathway from L-phenylalanine or L-
tyrosine (Rice-Evans et al., 1996) (Figure 4). Phenylalanine and tyrosine are very important 
amino acids in this pathway since these amino acids are the common precursors for the 
majority of the natural phenolic products (Valentão et al., 2005; Baptista et al., 2007).  
 
 
Figure 4. Biosynthesis pathways leading to formation of main groups of phenolic compounds (Ryan et al., 
1999). 
 
In the past few decades, mushrooms have received special attention for being rich sources of 
phenolic acids that are amongst the major contributors to their medicinal properties (Ferreira 
et al., 2009). Extensive knowledge of phenolic acids bioavailability is essential to understand 
the conjugations and bioactivities in the organism. Phenolic acids are a considerable group 
inside the polyphenol family, and there is evidence that when they are absorbed in the free 
form (as are mostly found in mushrooms), their absorption and conjugation (specially 
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glucuronation), follows the same pathways as that of flavonoids and other polyphenols 
(Cremin et al., 2001). 
 
Phenolic acids can be divided into two major groups, hydroxybenzoic acids and 
hydroxycinnamic acids, which are derived from non-phenolic molecules of benzoic and 
cinnamic acid, respectively. The biosynthesis of the main phenolic acids present in 
mushrooms is described in Figure 5. Chemically, these compounds have at least one 
aromatic ring in which at least one hydrogen is substituted by a hydroxyl group. It would be 
interesting to highlight that p-hydroxybenzoic and p-coumaric acids present in Adlay bran 
(Coix lacryma-jobi L.) were reported as anti-inflammatory agents (Huang et al., 2014), but as 
far as we know, there are no reports on phenolic acids from mushrooms. 
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Entry Starting Molecule  Enzyme Final compound 
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Figure 5. Main enzymes involved in the biosynthesis of phenolic acids through Shikimate pathway from L-
phenylalanine. 
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There are only a few reports in the literature describing the synthesis of metabolites from 
phenolic acids to evaluate their bioactivities in comparison with the corresponding parent 
compounds. Piazzon et al. (2012), as well as our research group (Heleno et al., 2013a, 
2014a), described the chemical or enzymatic synthesis of glucuronated, sulphated and 
methylated derivatives of several phenolic acids, obtaining structures similar to those formed 
in vivo after phenolic acid metabolism (Figure 6-8). 
 
 
 
                               
 
 
Figure 6. i) Glucuronidation of cinnamic acid (CA). CAGP- cinnamic acid glucuronide protected form, 2,3,4-
tri-O-acetyl-1-cinnamoyl-D-glucuronic acid methyl ester (Heleno et al., 2013a); ii) Methylation of CA. CAM- 
methyl 3-phenylacrylate (Heleno et al., 2014a). 
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Figure 7. i) Glucuronidation of p-coumaric acid (CoA). CoAGP- p-Coumaric acid glucuronide protected form, 
2,3,4-tri-O-acetyl-1-p-coumaroyl-D-glucuronic acid methyl ester (Heleno et al., 2014a) ii)-iv) Methylations of 
CoA. CoAM1- 3-(4-hydroxyphenyl) acrylate, CoA 
14 
 
 
 
Figure 8. i) Glucuronidation of p-hydroxybenzoic acid (HA). HAGP- p-hydroxybenzoic acid protected form, 
2,3,4-tri-O-acetyl-1-p-hydroxybenzoyl-D-glucuronic acid methyl ester (Heleno et al., 2013a). ii, iii, iv) 
Methylations of p-hydroxybenzoic acid, HAM1- methyl. 
 
All the glucuronated, methylated and sulphated compounds mentioned above, and the 
respective parental phenolic acids, were studied for their bioactivities namely, antioxidant 
(Piazzon et al., 2012), antimicrobial (Heleno et al., 2013a, 2014a) and antitumor (Heleno et 
al., 2014a) properties, in order to compare the biological activities of the parental compounds 
before and after in vivo metabolism. 
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1.4. Objectives  
 
We analyzed ethanolic extracts of ten wild mushroom species (Amanita caesaria (Scop.) 
Pers., Boletus aereus Bull., B. edulis Bull., B. flagrans Vittad., B. impolitus Fr., B. reticulatus 
Schaeff., Cantharellus cibarius Fr., Lactarius deliciosus (L. ex Fr.) S.F. Gray, Macrolepiota 
procera (Scop.) Singer and Morchella esculenta Fr.), collected in the Northeast of Portugal, 
and four cultivated species (Agaricus bisporus (J.E. Lange) Emil J. Imbach, A. bisporus 
Portobello (J.E. Lange) Emil J. Imbach, Pleurotus eryngii (DC.) Quél. and Pleurotus. 
ostreatus (Jacq. ex Fr.) P. Kumm.) were used in the present study for anti-inflammatory 
activity in LPS activated RAW 264.7 macrophages. Furthermore, after characterization of the 
extracts in terms of phenolic acids and related compounds, the identified individual parent 
molecules and their synthesised glucuronated and methylated derivatives were evaluated for 
the same bioactivity, in order to establish structure-activity relationships. 
The specific objectives were: 
1. To evaluate the anti-inflammatory activity of ethanolic extracts prepared from selected 
edible and wild mushrooms. 
2. To chemically characterize the mushroom extract in terms of phenolic acids by HPLC-
PDA (high performance liquid chromatography with photodiode array detection). 
3. To evaluate the anti-inflammatory activity of the phenolic acids identified in the 
extracts, as also of their synthesized glucuronated and methylated derivatives. 
4. Compare the activity of the extracts, individual phenolic acids and derivatives, in order 
to establish a structure-bioactivity relationship. 
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CHAPTER 2. EXPERIMENTAL SECTION 
 
2.1 Materials and Samples  
2.1.1. Mushroom samples  
Ten wild mushroom species (Amanita caesaria (Scop.) Pers., Boletus aereus Bull., B. edulis 
Bull., B. flagrans Vittad., B. impolitus Fr., B. reticulatus Schaeff., Cantharellus cibarius Fr., 
Lactarius deliciosus (L. ex Fr.) S.F. Gray, Macrolepiota procera (Scop.) Singer and 
Morchella esculenta Fr.), collected in the Northeast of Portugal, and four cultivated species 
(Agaricus bisporus (J.E. Lange) Emil J. Imbach, A. bisporus Portobello (J.E. Lange) Emil J. 
Imbach, Pleurotus eryngii (DC.) Quél. and Pleurotus. ostreatus (Jacq. ex Fr.) P. Kumm.) 
(Figure 9) were used in the present study. All species were deposited in the herbarium of the 
School of Agriculture in Polytechnic Institute of Bragança, and have been previously 
characterized by the research group in terms of nutritional value and chemical composition 
(including primary and secondary metabolites) (Barros et al., 2009; Grangeia et al., 2011; 
Heleno et al., 2011; Reis et al., 2011; Pereira et al., 2012; Reis et al., 2012; Heleno et al., 
2013b). 
Their antioxidant, antimicrobial and antitumor properties were also previously evaluated by 
the group (http://esa.ipb.pt/biochemcore/index.php/studied-mushrooms).  
 
 
Agaricus bisporus                                                         Agaricus bisporus Portobello 
( http://www.gbif.org/species)                                   ( http://www.mycelia.be/en/strain) 
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Amanita caesaria                                                    Boletus aereus                                
(http://www.cestaysetas.com)                                   (https://commons.wikimedia.org)  
 
Boletus edulis                                                    Boletus flagrans 
(http://www.mykoweb.com)                             (http://boletales.com) 
 
 Boletus impolitus                                                      Boletus reticulatus 
(http://monnuagedecreas.com)                                  (http://www.aranzadi.eus) 
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 Cantharellus cibarius                                                  Lactarius deliciosus                 
(http://www2.muse.it)                                                   (https://www.flickr.com)  
 
Macrolepiota procera                                                   Morchella esculenta 
(http://www.aranzadi.eus)                                             (https://commons.wikimedia.org) 
 
 
Pleurotus eryngii                                                           Pleurotus ostreatus 
(http://www.boletsdesoca.com)                                     (http://www.mykoweb.com)            
 
                                       Figure 9. Studied mushroom species. 
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2.1.2. Reagents and solvents 
Acetonitrile 99.9% was of high-performance liquid chromatography (HPLC) grade from Lab-
Scan (Lisbon, Portugal). Dulbecco’s modified Eagle’s minimum essential medium (DMEM), 
fetal bovine serum (FBS), penicillin, streptomycin, Griess reagent system (Promega), DMSO, 
Glutamine, Non-essential amino acids, sulphorodamine B (SRB) and lipopolysaccharide 
(LPS) were obtained from Sigma-Aldrich Co. (Saint Louis, MO, USA). All other chemicals 
and solvents were of analytical grade and purchased from common sources. 
 
2.1.3. Equipment 
The equipment used in the present work is listed in Table 2. 
 
Table 2. List of equipment used in the present study. 
Equipment Company Application 
Digital balance KERN ABS-N Weight mushroom sample and reagents 
Magnetic stirrer ARE VELP Scientifica Stirring the samples for proper extraction 
Rotary evaporator Heidolph (Hei-Vap) Evaporation of the extraction solvent 
Ultrasound bath ELMA TRANSSONIC T 
460/H 
Proper dissolution of the extracts 
HPLC-PDA UFLC, Shimadzu 
Coperation, Kyoto, Japan 
Characterization of the extracts in terms of 
phenolic acids 
Air incubator VWR INCU- Line Preparation of culture media 
CO2 incubator Heal force HF 151 Cells growth under controlled temperature, 
CO2 and humidity  
Inverted Microscope Nikon ECLIPSE TS100 Analysis of the morphology of RAW 267.6 
cells 
Vertical laminar flow bench Telstar Technologies 
Av/30/70 
Safety manipulation of the animal cells 
Centrifuge HERMLE Z 206 A Obtaining  RAW 267.6 cell’s suspensions  
Microscope Motic BA80 Series Counting RAW 267.6 cells 
Inverted Microscope Nikon ECLIPSE TS100 Analysis of the morphology of RAW 267.6 
cells 
Microplates reader ELX800 Biotek Measuring the absorbance at 540nm 
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2.2. Methodology 
2.2.1. Extracts preparation 
Dried mushroom powder of each species (0.5 g) was extracted with ethanol (15 mL), by 
maceration with stirring for 1 h. Then, the extract was filtered through Whatman no 4 filter 
paper and the extraction procedure was repeated one more time. The filtrate was rotary 
evaporated to remove ethanol (Figure 10) and the extraction yield was calculated by 
measuring the extract weight in relation to the initial mass sample (Table 3). 
 
                                    Figure 10. Extract solutions and ethanol removal. 
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Table 3. Extraction yields obtained for each mushroom species. 
Mushroom species 
Final mass of extract 
(mg) 
Extraction yield 
(%) 
Agaricus bisporus 29.0  0.6 5.80 
Agaricus bisporus portobelo 22.3  0.4 4.50 
Amanita caesaria 23.8  0.4 4.76 
Boletus aereus 40.9  0.8 8.18 
Boletus edulis 36.0  0.8 7.20 
Boletus flagrans 25.4  0.6 5.08 
Boletus impolitus 24.0  0.7 4.80 
Boletus reticulatus 43.2  0.9 8.64 
Cantharellus cibarius 21.2  0.6 4.24 
Lactarius deliciosus 23.8  0.4 4.76 
Macrolepiota procera 26.8  0.5 5.36 
Morchella esculenta 22.0  0.4 4.44 
Pleurotus eryngii 49.0  0.8 9.80 
Pleurotus ostraetus 17.2  0.3 3.44 
 
2.2.2. Chemical characterization of the extracts 
The dry mass of each mushroom extract was re-dissolved in water/ethanol (50:50, v/v) 
(Figure 11) and filtered through a 0.22 µm nylon disposable filter for HPLC analysis. The 
analysis was performed using a Shimadzu 20A series ultra-fast liquid chromatograph (UFLC, 
Shimadzu Coperation, Kyoto, Japan). Separation was achieved on a Waters Spherisorb S3 
ODS2 C18 column (3 µm, 150 mm x 4.6 mm) column thermostatted at 35ºC. The solvents 
used were: (A) 0.1% formic acid in water, (B) acetonitrile. The elution gradient established 
was 10% B to 15% B over 5 min, 15–25% B over 5 min, 25–35% B over 10 min, isocratic 
50% B for 10 min, and re-equilibration of the column, using a flow rate of 0.5 mL/min. 
Detection was carried out in a photodiode array detector (PDA), using 280 nm as the 
preferred wavelength. 
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Figure 11. Extract solutions ready to be filtered for HPLC analysis. 
 
The phenolic acids (group of phenolic compounds identified in the samples) were quantified 
by comparison of the area of their peaks recorded at 280 nm with calibration curves obtained 
from commercial standards of each compound: p-hydroxybenzoic acid (y = 113523x, 
R2=0.999), p-coumaric acid (y = 433521x, R2=0.998) and cinnamic acid (y = 583527x, 
R2=0.998), 5 to 80 μg/mL. The results were expressed as milligrams per mL of extract.  
 
2.2.3. Phenolic acids and synthesised derivatives 
p-Hydroxybenzoic acid, p-coumaric acid and cinnamic acid, identified in the mushroom 
extracts, were purchased from Sigma-Aldrich Co. (Saint Louis, MO, USA). Methylated and 
glucuronated derivatives of the identified compounds (Figure 6,7 and 8) were previously 
synthesized and completely characterized by the authors (Heleno et al., 2013a; Heleno et al., 
2014). 
 
2.2.4. Evaluation of the anti-inflammatory activity 
 
2.2.4.1. Preparation of cells growth medium.  
DMEM was supplemented with 10% heat-inactivated FBS, 1% penicillin and streptomycin, 
1% glutamine and 1% non-essential amino acid. This preparation procedure was carried out 
in the vertical laminar flow bench in order to offer optimum protection against 
contaminations. It was then stored in an incubator with natural air circulation. 
 
2.2.4.2 Cells treatment.  
For the anti-inflammatory activity assay, the ethanolic extracts were dissolved in water at 8 
mg/mL, while the identified individual compounds and their synthesised methylated and 
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glucuronated derivatives were dissolved in DMSO at 50% concentration in stock solution. 
For the different assays, the solutions were then submitted to further dilutions (400 µg/mL to 
50 µg/mL and 2500 µM to 39 µM for the extracts and compounds, respectively) in order to 
determine effective concentrations. 
 
The mouse macrophage-like cell line RAW 264.7 was cultured in DMEM medium 
supplemented with 10% heat-inactivated FBS, glutamine and antibiotics at 37 °C under 5% 
CO2, in humidified air. 
 
For each experiment, cells were detached with a cell scraper. A cell density of 5x105 cells/mL 
was used, and the proportion of dead cells was less than 5%, according to Trypan blue dye 
exclusion test. 
 
Cells were seeded in 96-well plates at 150,000 cells/well and allowed do attach to the plate 
overnight. Then, cells were treated with the different concentrations of each one of the 
extracts for 1h. Dexamethasone (50 µM) was used as a positive control for the experiment. 
The following step was the stimulation with LPS (1 µg/mL) for 18h. The effect of all the 
tested samples in the absence of LPS was also evaluated, in order to observe if they induced 
changes in nitric oxide (NO) basal levels. In negative controls, no LPS was added. Both 
extracts and LPS were dissolved in supplemented DMEM. 
 
2.2.4.3. Nitric oxide determination. 
 For the determination of nitric oxide, Griess Reagent System kit was used, which contained 
sulphanilamide, N-(1-napthyl) ethylenediamine hydrochloride (NED) and nitrite solutions. A 
reference curve of the nitrite (sodium nitrite 100 µM to 1.6 µM; y=0.0064x+0.1311, 
R2=0.9981) was prepared in a 96-well plate. The cell culture supernatant (100 µL) was 
transferred to the plate and mixed with Sulphanilamide and NED solutions, 5-10 minutes 
each, at room temperature. 
 
The nitric oxide produced was determined by measuring the absorbance at 540 nm 
(microplate reader) (Figure 12), and by comparison with the standard calibration curve. The 
percentage of inhibition of the NO production was calculated, for each sample concentration, 
by the equation: [(Substrate concentration - Basal cells)/LPS – Basal cells] x100  
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For an easier comparison of the results, EC50 values were calculated based on 50% of 
inhibition of NO production. 
            A)                                                                                    B) 
 
Figure 12. Microplates showing the NO assay with A) ethanolic mushroom extract and B) phenolic acids, 
already stimulated with 1 µg/mL LPS and Griess Reagent kit to be read at 540 nm. 
 
2.2.5. Statistical analysis 
For all the experiments three samples were analyzed and all the assays were carried out in 
triplicate. The results are expressed as mean values ± standard deviation (SD). The 
differences between the different samples were analyzed using one-way analysis of variance 
(ANOVA) followed by Tukey’s honestly significant difference post hoc test with α = 0.05, 
coupled with Welch’s statistic. This treatment was carried out using SPSS v. 22.0 program. 
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CHAPTER 3. RESULTS AND DISCUSSION 
 
Ethanolic extracts were prepared from ten wild mushroom species Amanita caesaria, Boletus 
aereus, B. edulis, B. flagrans, B. impolitus, B. reticulatus, Cantharellus cibarius, Lactarius 
deliciosus, Macrolepiota procera, Morchella esculenta, and four cultivated species Agaricus 
bisporus, A. bisporus Portobello, Pleurotus eryngii. and Pleurotus. ostreatus. The compounds 
identified in the extracts by HPLC-PDA are presented in Table 4. 
 
Table 4. Compounds identified in the mushroom ethanolic extracts by HPLC-PDA. 
Mushroom species 
Extraction 
Yield (%) 
p-Hydroxybenzoic 
acid  (µg/g) 
p-Coumaric acid 
(µg/g) 
Cinnamic acid 
(µg/g) 
Agaricus bisporus 6.9 ± 0.7abcd nd nd 149 ± 2d 
Agaricus bisporus 
portobelo 
6.0 ± 0.1bcd nd nd 11 ± 1hi 
Amanita caesaria 5.4 ± 0.5cd 57 ± 3e nd 156 ± 3d 
Boletus aereus 7.7 ± 0.6abc 43 ± 1f 74 ± 1b 50 ± 3f 
Boletus edulis 10.4 ± 0.5ª nd nd 14.2 ± 0.4gh 
Boletus flagrans 4.9 ± 0.3cd nd nd 6.1 ± 0.3i 
Boletus impolitus 4.1 ± 0.5d 125 ± 9c 45 ± 2c 505 ± 12c 
Boletus reticulatus 9.5 ± 0.3ab nd nd 20.3 ± 0.1g 
Cantharellus cibarius 4.0 ± 0.3d 151 ± 2b nd 71 ± 1e 
Lactarius deliciosus 3.7 ± 0.4d 108 ± 5d nd 67 ± 1e 
Morchella esculenta 4.0 ± 0.8d nd nd 71 ± 3e 
Macrolepiota procera 3.7 ± 0.4d nd nd 522 ± 1b 
Pleurotus eryngii 10.1 ± 0.6a nd nd 16 ± 1gh 
Pleurotus ostraetus 4.0 ± 0.6d 297 ± 5a 171 ± 1a 619 ± 3a 
nd- not detected. ANOVA In each column, different letters mean statistical significant differences (p<0.05) 
between samples. 
 
NO is a signalling molecule that plays critical role in the pathogenesis of inflammation 
(Sharma et al., 2007). Although physiological levels of NO are required for events such as 
vasodilation, angiogenesis, and neurotransmission, the overproduction of NO under 
pathological conditions can be a toxic and pro-inflammatory mediator that induces 
inflammation (Guzik et al., 2003). Therefore, the inhibition of NO production under 
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inflammatory stimuli is relevant to the development of anti-inflammatory agents (Biesalski, 
2007). The ability of ethanolic extracts of the fourteen different mushroom species to 
modulate the production of inflammatory mediator NO was evaluated in RAW 264.7 
macrophages by pre-treating cells with various concentrations of the mushroom extract 
before stimulation with 1 µg/mL LPS. 
LPS is a cell wall component of Gram-negative bacteria, and plays a central role in the 
pathogenesis of several diseases (Sachithanandan et al., 2011). When macrophages are 
exposed to LPS, the LPS binds to receptors that activate several signalling pathway that 
intern result in activation of NF-κB. When the NF-κB signalling pathway is activated, 
macrophages secrete NO and pro-inflammatory cytokines. Hence, natural agents that regulate 
the production of various cytokines and suppress the overproduction of NO may have 
protective roles in inflammation-related diseases (Nam, 2006). 
The effects of the ethanolic extracts on the production of inflammatory mediators (NO) in 
RAW 264.7 macrophages, upon stimulation with LPS, are shown in Figure 13. The results 
indicate that some extracts inhibited LPS-induced NO production in a dose-dependent 
manner. For an easier comparison of the results, EC50 values were calculated based on 50% 
of inhibition of NO production (Table 5). 
 
Table 5. EC50 values responsible for 50% of reduction of NO production in RAW 264.7 cell line. 
 
EC50 values correspond to 50% of inhibition of the NO production in comparison with the negative control 
(100% of NO production). In the columns, different letters mean statistical significant differences (p<0.05) 
between samples. Dexamethaxone EC50 value = 16 ± 2 µg/mL.         
 
Mushroom species 
EC50 values 
(µg/mL) 
Mushroom species 
EC50 values 
(µg/mL) 
Agaricus bisporus 190 ± 6ef Boletus reticulatus 378 ± 28ab 
Agaricus bisporus portobelo >400ª Cantharellus cibarius 202 ± 17e 
Amanita caesaria 186 ± 7ef Lactarius deliciosus 253 ± 14d 
Boletus aereus 357 ± 3b Macrolepiota procera 162 ± 2g 
Boletus edulis >400ª Morchella esculenta 287 ± 9c 
Boletus flagrans >400ª Pleurotus eryngii 388 ± 17a 
Boletus impolitus 166 ± 10fg Pleurotus ostraetus 96 ± 1h 
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The most efficient species was P. ostreatus (96 ± 1 µg/mL), followed by M. procera (162 ± 2 
µg/mL), B. impolitus (166 ± 10 µg/mL) and A. bisporus (190 ± 6 µg/mL). These results are in 
agreement with the reports of Moro et al. (2012) and Gunawardena et al. (2014) that 
described anti-inflammatory activity, by decreasing NO levels in RAW 264.7 cells, of 
ethanolic and methanolic extracts of A. bisporus, C. cibarius, L. deliciosus and P. ostreatus 
(Table 5). The ethanolic extracts from A. bisporus Portobello, B. edulis and B. flagrans 
appeared as the less active, showing EC50 values above 400 µg/mL. Moro et al. (2012) 
reported some activity in the case of methanolic extracts of B. edulis with 10% inhibition of 
NO production at concentrations of 500 µg/mL. 
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Figure 13. . Effects of the ethanolic mushroom extracts showing the % NO produced by RAW 264.7 cell line. 
Mean values and standard errors, expressed in relation to the negative control (without extract) - 100% of 
production. 
 
Although many substances may participate in the anti-inflammatory activity, phenolic 
compounds have been largely recognised as natural molecules with anti-inflammatory 
effects. Positive correlations have been found between phenolic compounds and anti-
inflammatory effects (Cheung, Cheung, & Ooi, 2003; Kim et al., 2008). In the present study, 
it was also observed that the extract with the highest anti-inflammatory activity showed the 
highest levels of cinnamic and phenolic acids.  
 
To demonstrate this supposition, the activity of the individual compounds present in the 
extracts were further evaluated (Table 4). Cinnamic acid (CA) showed the highest anti-
inflammatory activity presenting the lowest EC50 values (182 ± 16 µM), followed by p-
hydroxybenzoic (239 ± 29 µM) and p-coumaric (442 ± 33 µM) acids. These results are in 
agreement with the ones reported by our research group for the antimicrobial activity of these 
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compounds, where cinnamic acid also revealed the strongest activity followed by p-
hydroxybenzoic and p-coumaric acids (Heleno et al., 2014a).  
 
As phenolic acids are metabolized in the organism and suffer conjugation reactions 
originating different metabolites such as glucuronated and methylated derivatives, a change 
in their effects or activity may also occur. Thus, the bioactivity of the parent molecule can be 
increased, decreased or maintained (Heleno et al., 2015). Hereby the glucuronated and 
methylated derivatives of the considered acids were analysed and compared to the one of the 
parent molecule (Figure 14). Among the glucuronated derivatives, CoA-GP (glucuronated 
derivative of p-coumaric acid) presented strong anti-inflammatory activity (58 ± 5 µM), 
being comparable to the activity of the standard dexamethaxone (40 ± 4 µM), followed by the 
glucuronated derivatives of cinnamic (CA-GP) (179 ± 71 µM) and p-hydroxybenzoic (HA-
GP) (1901 ± 104 µM) acids. Regarding the methylated derivatives, those of p-coumaric acid 
presented higher activity than the ones of cinnamic or p-hydroxybenzoic acids; in particular, 
the methylated derivative CoA-M1, with an ester instead of the carboxylic group, revealed 
very strong activity (35 ± 2 µM), very close to the dexamethaxone value (40 ± 4 µM). 
 
Comparing the activity of each parent molecule and the corresponding glucuronated and 
methylated derivatives, the order was as follows: p-hydroxybenzoic acid: HA > HA-M3 > 
HA-M2 >HA-M1 > HA-GP; p-coumaric acid: CoA-M1 > CoA-GP > CoA-M2 > CoA-M3 > 
CoA; and cinnamic acid: CA-GP > CA > CA-M. p-Hydroxybenzoic acid showed higher 
activity than the corresponding derivatives, with HA-M3 as the most active compound; the 
decreased anti-inflammatory activity observed for HA-M1, HA-M2 and HA-GP could be 
explained by the esterification of the carboxylic group. On the contrary, all p-coumaric acid 
derivatives showed higher activity than the parent molecule (CoA), particularly the 
methylated compound CoA-M1 and CoA-GP, suggesting that in this case the esterification of 
the carboxylic group together with the free OH group in para position could be relevant 
features for their anti-inflammatory activity. The glucuronated derivative of cinnamic acid 
(CA-GP) maintained its activity in comparison with the parent molecule (CA), while the 
methylated one (CA-M) decreased it. 
 
These results are in relatively good agreement with the ones previously reported by our 
research group comparing the antimicrobial activity of p-hydroxybenzoic, p-coumaric and 
cinnamic acids and their respective methylated and glucuronated derivatives. The 
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methylation of p-hydroxybenzoic and cinnamic acids decreased the antimicrobial activity, 
while the methylation of p-coumaric acid increased it (Heleno et al., 2014a); moreover, the 
glucuronidation of the parent molecules also decreased the antimicrobial activity, except for 
HA-GP that showed higher antifungal activity against some pathogenic strains (Heleno et al., 
2013a). 
 
 
Table 6. EC50 values responsible for 50% of reduction of NO production in RAW 264.7 cell line 
p-Hydroxybenzoic acid  
and derivatives 
p-Coumaric acid  
and derivatives 
Cinnamic acid  
and derivatives 
HA 239 ± 29
c CoA 442 ± 33a CA 182 ± 16b 
HA-GP 1901 ± 104
a CoA-GP  58 ± 5c CA-GP 179 ± 17b 
HA-M1 1825 ± 120
a CoA-M1 35 ± 2c CA-M 224 ± 16a 
HA-M2 526  ± 26
b CoA-M2 128 ± 10b   
HA-M3 509 ± 47
b CoA-M3 129 ± 6b   
   
EC50 values correspond to 50% of inhibition of the NO production in comparison with the negative control 
(100% of NO production). In each column, different letters mean statistical significant differences (p<0.05) 
between compounds. Dexamethaxone EC50 value = 40 ± 4 M. 
 
 
 
 
 
 
 
 
 
 
 
 
Screening in phenolic extracts, individual parent molecules and synthesized glucuronated and methylated derivatives 
31 
Oludemi Taofiq Ayodele 
 
 
 
 
 
Figure 14. Effects of the synthesised derivatives and parent molecules showing the % NO produced by RAW 
264.7 cell line. Mean values and standard errors, expressed in relation to the negative control (without 
compound) - 100% of production. 
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CHAPTER 4. CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES  
 
In this study, we investigated the anti-inflammatory effects of ethanolic extracts from ten 
wild mushroom species and four cultivated species using the LPS-stimulated macrophage cell 
RAW264.7 as a model system. Although we observed variations in the anti-inflammatory 
activity among mushroom species, the results clearly indicate that the most efficient species 
were P. ostreatus (96 ± 1 µg/mL), followed by M. procera (162 ± 2 µg/mL), B. impolitus 
(166 ± 10 µg/mL) and A. bisporus (190 ± 6 µg/mL). They all had an inhibitory effect on the 
production of the pro-inflammatory mediator NO due to the presence of important bioactive 
compounds. Therefore, each ethanolic extract was chemically characterized in terms of 
phenolic acids and the extracts were found to contain several active molecules (p-
hydroxybenzoic acid, p-coumaric acid and cinnamic acid), which have been suggested to play 
an important role in controlling inflammatory diseases.  
Furthermore, the individual phenolic acids present in the extracts and their synthesized 
derivatives were further evaluated in the same model system, LPS-stimulated macrophage 
cells RAW264.7. Cinnamic acid (CA) showed the highest anti-inflammatory activity 
presenting the lowest EC50 values (182 ± 16 µM), followed by p-hydroxybenzoic (239 ± 29 
µM) and p-coumaric (442 ± 33 µM) acids. Comparing the activity of each parent molecule 
and the corresponding glucuronated and methylated derivatives, the order was as follows: p-
hydroxybenzoic acid: HA > HA-M3 > HA-M2 >HA-M1 > HA-GP; p-coumaric acid: CoA-
M1 > CoA-GP > CoA-M2 > CoA-M3 > CoA; and cinnamic acid: CA-GP > CA > CA-M. 
These results suggest that the phenolic acids present in the ethanolic mushroom extracts may 
contain some useful preventive and therapeutic agents against inflammatory responses. 
 
Overall, the mushroom species: P. ostreatus, M. procera, B. impolitus and A. bisporus 
revealed the strongest anti-inflammatory potential presenting the highest inhibition of NO 
production. These mushroom species also revealed the highest concentration in cinnamic 
acid, which was also the individual compound that presented the strongest anti-inflammatory 
activity and, therefore, could play an important role in the observed activity.  However, the 
conjugation reactions occurring in the organism can change the chemical structure of 
cinnamic and phenolic acids increasing or decreasing their in vivo anti-inflammatory activity. 
The possible metabolites previously synthesised by the authors and tested in the present work 
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are still displaying activity, in some cases like CoA-GP and CoA-M1 higher than the parent 
compound and very close to the activity exhibited by dexamethaxone used as anti-
inflammatory standard.  
 
This research work has demonstrated the importance of mushrooms as potential bio-factories 
for the production of natural anti-inflammatory compounds. The bioactivities of these 
compounds are exhibited through the downregulation of different types of inflammatory 
mediators. In addition to the high potential application of anti-inflammatory molecules from 
mushrooms in medical applications, they can also be used in cosmeceutical products as 
natural active ingredients.  
However, the future medical application of anti-inflammatory compounds isolated from 
mushrooms faces several challenges. Firstly, most of the studied mushrooms are not 
cultivable in greenhouses, and thus their availability is both seasonal and highly affected by 
climatic changes. Secondly, the contents of the bioactive ingredients vary widely between 
samples, dependent on the collection time and procedure, the season, the environment and the 
genotype. Thirdly, mushroom cultivation needs to be run according to the current Good 
Manufacturing Practice (cGMP) requirements for the production of bioactive medicinal 
compounds. Fourthly, there is a lack of validated standard testing protocols to guarantee the 
quality and the efficacy of mushroom products for pharmaceutical applications. 
Hence, more research should be done on the development of mushroom cultivation and 
extraction processes under fully sterile conditions so as to obtain bioactive metabolites for 
pharmaceutical applications. Also, further experiments are needed to be able to elucidate the 
anti-inflammatory mechanism of action of these natural biological agents. 
The results presented in this work were published in Food Research International, a journal 
from Elsevier: 
Oludemi Taofiq, Ricardo C. Calhelha, Sandrina Heleno, Lillian Barros, Anabela Martins, 
Celestino Santos-Buelga, Maria João R.P. Queiroz, Isabel C.F.R. Ferreira. The contribution 
of phenolic acids to the anti-inflammatory activity of mushrooms: screening in phenolic 
extracts, individual parent molecules and synthesized glucuronated and methylated 
derivatives. Accepted for publication in Food Research International (24/07/2015). 
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